Apo-Citalopram

Maklumat utama

  • Nama dagangan:
  • Apo-Citalopram Tablet
  • Perubatan domain:
  • Manusia
  • Jenis perubatan:
  • Ubat Allopathic

Dokumen

Penyetempatan

  • Terdapat dalam:
  • Apo-Citalopram Tablet
    Malaysia
  • Bahasa:
  • Bahasa Melayu

Maklumat lain

Status

  • Sumber:
  • NPRA - National Pharmaceutical Regulatory Agency - Bahagian Regulatori Farmasi Negara
  • Nombor kebenaran:
  • MAL08061582
  • Kemaskini terakhir:
  • 31-08-2017

Risalah Maklumat Pesakit: ciri produk - komposisi, petunjuk, kesan sampingan, dos, interaksi, tindak balas buruk, kehamilan, penyusuan

Risalah Maklumat Ubat untuk Pengguna (RiMUP

)

No. Mukasurat 1

APO-CITALOPRAM TABLET

Citalopram Hydrobromide (20mg)

Apakah yang ada pada risalah

ini

Apakah kegunaan Apo-

Citalopram

Bagaimana Apo-Citalopram

berfungsi

Sebelum menggunakan Apo-

Citalopram

Cara menggunakan Apo-

Citalopram

Semasa menggunakan Apo-

Citalopram

Kesan-kesan sampingan

Cara penyimpanan dan

pelupusan Apo-Citalopram

Maklumat lanjut

Pengilang dan Pemegang

Pendaftaran Produk

Tarikh kemaskini RiMUP

Apa kegunaan Apo-Citalopram

APO-CITALOPRAM adalah ubat

preskripsi yang mengandungi

bahan aktif

citalopram

hydrobromide

. APO-

CITALOPRAM digunakan untuk

melegakan tanda-tanda

kemurungan dan untuk mencegah

kemunculan semula atau

perulangan penyakit.. Rawatan

dengan jenis ubat ini adalah yang

paling selamat dan berkesan

apabila anda dan doktor anda

menjalinkan komunikasi yang

baik berkenaan dengan perasaan

anda.

Ubat ini juga boleh digunakan

untuk rawatan gangguan panik

dengan atau tanpa

agoraphobia

(perasaan takut kepada

persekitaran sosial atau keadaan)

dan gangguan obsesif kompulsif

(OCD) juga.

Bagaimana Apo-Citalopram

berfungsi

APO-CITALOPRAM tergolong

dalam kelas ubat yang digelar

sebagai

selective serotonin

reuptake inhibitor

(SSRI). Ia

berfungsi dengan meningkatkan

jumlah bahan-bahan semula jadi

tertentu di dalam otak yang

diperlukan untuk mengekalkan

keseimbangan mental.

Sebelum mengambil Apo-

Citalopram

-

Bila tidak boleh mengambil

Jika anda alah kepada sebarang

produk yang mengandungi

citalopram, atau jika anda sedang

menjalani rawatan dengan

monoamine oxidase inhibitor

(MAOI).

-

Sebelum mula mengambil

Sebelum anda mula mengambil

APO-CITALOPRAM, doktor

anda perlu tahu:

Apa-apa masalah perubatan

lain yang anda mungkin

mengalami termasuk

penyakit jantung, sawan;

Sebarang sejarah penyakit

mania atau hipomania;

Sama ada anda merancang

untuk hamil, sedang hamil

atau menyusu bayi;

Menpunyai sejarah

penyalahgunaan dadah atau

pernah ada pemikiran

membunuh diri;

Kehadiran sebarang

pendarahan atau gangguan

pembekuan darah;

Jika anda seorang pesakit

kencing manis.

Jika mengambil ubat-ubat lain

Beritahu doktor anda jika anda

mengambil mana-mana preskripsi

atau ubat over-the-kaunter.

Citalopram tidak boleh digunakan

dalam kombinasi dengan ubat-

ubat yang berikut:

Monoamine oxidase inhibitor

(MAOI). Citalopram boleh

dimulakan 14 hari selepas

menghentikan rawatan dengan

irreversible

MAOI dan sekurang-

kurangnya satu hari selepas

menghentikan rawatan dengan

reversible

MAOI (RIMA),

moclobemide

Sekurang-kurangnya 7 hari harus

berlalu selepas menghentikan

rawatan Citalopram sebelum

memulakan MAOI atau RIMA.

- Ubat-ubat yang diketahui

mempengaruhi fungsi platelet

seperti antipsikotik atipikal dan

phenothiazines

, antidepresan

tricyclic, aspirin

dan ubat anti-

radang bukan steroid (NSAID).

Metoprolol

(agen untuk

menurunkan tekanan darah tinggi)

Cimetidine

(untuk merawat

gangguan perut)

Cara menggunakan Apo-

Citalopram

- Berapa banyak harus digunakan

Antidepresan:

APO-CITALOPRAM perlu

diambil sebagai dos tunggal 20mg

setiap hari.

Pencapaian tahap dos yang

berkesan adalah berbeza untuk

setiap orang. Oleh sebab itu,

doktor mungkin meningkatkan

dos anda secara beransur-ansur

sehingga 60mg sehari semasa

rawatan. Ia adalah sangat penting

bahawa anda mengambil APO-

CITALOPRAM tepat sepertimana

yang diarahkan oleh doktor.

Gangguan panik:

Dos awal untuk gangguan panik

harus bermula dari 10mg setiap

hari dan meningkat secara

beransur-ansur, sehingga 60mg

setiap hari mengikut keperluan

pesakit.

Jika keadaan ini tidak dikawal

Risalah Maklumat Ubat untuk Pengguna (RiMUP

)

No. Mukasurat 2

selepas 3 bulan rawatan,

berunding dengan doktor kerana

anda mungkin memerlukan

rawatan untuk tempoh yang

berpanjangan.

Gangguan obsesif kompulsif:

Bagi orang dewasa, dos

permulaan adalah 20mg, dan

meningkat secara beransur-ansur

sehingga 60mg setiap hari.

Untuk pesakit warga tua, dos yang

disyorkan adalah 20mg, dan

boleh ditingkat kepada maksimum

40mg setiap hari.

Kanak-kanak tidak digalakkan

untuk mengambil ubat ini kerana

keselamatan dan keberkesanan

ubat in belum dikenalpastikan

untuk golongan ini.

-

Bila perlu digunakan

APO-CITALOPRAM perlu

diambil mengikut arahan doktor

atau label yang dilampirkan

dengan ubat ini. Telan tablet

dengan air tanpa mengunyahnya.

- Berapa lama perlu digunakan

Jangan sekali-kali menambah atau

mengurangkan dos APO-

CITALOPRAM anda, atau

kepada mereka di bawah jagaan

anda melainkan jika diarah oleh

doktor anda. Anda juga

diingatkan supaya tidak berhenti

mengambil ubat ini tanpa

berunding dengan doktor terlebih

dahulu.

-

Jika terlupa menggunakan

Ambil dos yang terlepas sebaik

sahaja anda ingat, melainkan jika

ia sudah hampir masa untuk dos

seterusnya seperti yang telah

dijadualkan. Untuk keadaan

sebegini, abaikan dos yang

terlepas. Jangan mengambil dos

tambahan untuk menggantikan

dos yang terlepas.

-

Jika mengambil berlebihan

(Terlebih dos)

Hubungi doktor anda atau hospital

jabatan kecemasan terdekat

walaupun anda tidak rasa

sebarang kesakitan atau

ketidakselesaan.

Gejala-gejala dos berlebihan

termasuk sifat ingin tidur

(mengantuk), koma, ekspresi

menjadi kaku, episod konvulsi

grand mal

(sawan umum),

takikardia sinus (kadar jantung

lebih cepat daripada biasa), ritme

nodus yang berlaku sekali-sekala

(ritma jantung), berpeluh Loya,

muntah-muntah. sianosis (warna

kulit bertukar menjadi biru),

hiperventilasi

Semasa menggunakan Apo-

Citalopram

Perkara yang perlu dilakukan

Ambil ubat anda mengikut

arahan doktor.

Maklumkan kepada semua

doktor, doktor gigi dan ahli

farmasi yang merawat anda

bahawa anda sedang

menggunakan Apo-Citalopram.

Beritahu doktor anda dengan

segera jika anda menjadi hamil

semasa menggunakan ubat ini.

Perkara yang tidak boleh

dilakukan

Jangan

berhenti

menggunakan

ubat ini kecuali diarahkan oleh

doktor anda.

Jangan

mula

mengambil

sebarang

ubat

baru

tanpa

berbincang dengan doktor atau

ahli farmasi anda.

Jangan

berkongsi

Apo-

Citalopram

dengan

sesiapa,

walaupun

mereka

mempunyai

simptom

atau

penyakit

yang

sama.

Perkara yang perlu diberi

perhatian

Ubat ini mungkin menyebabkan

pemikiran membunuh diri dalam

kanak-kanak dan remaja. Ubat

antidepressan boleh meningkatkan

risiko pemikiran dan tingkah laku

membunuh diri dalam kanak-

kanak dan remaja yang

mempunyai gangguan depresi

major dan gangguan psikiatri

yang lain.Keluarga dan penjaga

dinasihati untuk memerhati

pesakit secara rapat dan

berkomunikasi dengan

doktor.Produk ini tidak

disarankan untuk kegunaan

kanak-kanak.

Elakkan tugas-tugas yang

berpotensi berbahaya seperti

memandu kereta atau

mengendalikan mesin berbahaya

sehingga anda yakin bahawa ubat-

ubatan ini tidak menjejaskan

kecerdasan mental atau koordinasi

fizikal anda.

Jika anda hamil dan mengambil

citalopram, atau antidepresan lain,

anda perlu berbincang dengan

doktor mengenai risiko dan

manfaat daripada pelbagai pilihan

rawatan lain.

Ia adalah sangat penting bahawa

anda TIDAK berhenti mengambil

ubat-ubatan ini tanpa nasihat

doktor.

Kesan-kesan sampingan

Kesan-kesan sampingan

mengambil Citalopram biasanya

bersifat ringan dan sementara

saja. Kesan-kesan sampingan

adalah paling menonjol pada dua

minggu pertama permulaan

rawatan. Kesan-kesan sampingan

termasuk loya, mengantuk, mulut

kering, berpeluh banyak dan

ketaran. Walau bagaimanapun,

jika anda rasa apa-apa

ketidakselesaan selain daripada

yang disenaraikan diatas, beritahu

kepada doktor anda secepat

mungkin.

Anda boleh melaporkan sebarang

kesan sampingan atau kesan

advers ubat

terus kepada Pusat

Risalah Maklumat Ubat untuk Pengguna (RiMUP

)

No. Mukasurat 3

Pemantauan Kesan Advers Ubat

Kebangsaaan melalui No Tel: 03-

78835550, atau laman web

portal.bpfk.gov.my (

Consumers

Reporting)

Cara penyimpanan dan

pelupusan Apo-Citalopram

-

Penyimpanan

Anda diingatkan supaya

menyimpan APO-CITALOPRAM

dan semua ubat-ubatan di tempat

yang selamat, jauh dari kanak-

kanak.

Jangan gunakan ubat ini selepas

tarikh luput yang ditulis seperti di

bekas.

Simpan APO-CITALOPRAM di

bawah suhu 25° C.

-

Pelupusan

Sekiranya anda masih mempunyai

baki ubat ini selepas berhenti

mengambilnya atas arahan doktor

atau ubat ini telah melepasi tarikh

luputnya, sila rujuk kepada ahli

farmasi tentang langkah yang

perlu diambil.

Ubat-ubatan tidak harus

dilupuskan melalui air buangan

atau sisa isi rumah. Sila rujuk

kepada ahli farmasi anda

mengenai cara yang betul untuk

melupuskan ubat yang tidak

diperlukan lagi. Langkah-langkah

ini dapat membantu melindungi

alam sekitar.

Maklumat lanjut

-

Rupa dan warna produk

Tablet 20mg adalah berwarna

putih, bentuk bujur dwicembung,

bersalut filem, terukir 20 di satu

permukaan dan perkataan APO

pada permukaan yang lain.

-

Bahan-bahan Kandungan

- Bahan aktif:

Citalopram

Hydrobromide

- Bahan tidak aktif

: Lactose

Monohydrate(Spray dried) NF,

Microcrystalline Cellulose (PH

102) NF, Croscarmellose Sodium

NF, Magnesium Stearate NF,

Hydroxyethyl Cellulose (Type 250

L), NF, Polyethylene Glycol 8000,

Titanium Dioxide

Purified

Water

-

Nombor MAL

APO-CITALOPRAM 20mg tab

(MAL08061582A)

Pengilang

Apotex Inc – Etobicoke Site

50 Steinway Boulevard

Etobicoke, Ontario

Canada M9W 6Y3

Pemegang Pendaftaran Produk

Pharmaforte (M) Sdn Bhd

2, Jalan PJU 3/49

Sunway Damansara

47810 Petaling Jaya

Tarikh Kemaskini RiMUP

8/1/2015

Nombor siri

BPFK(R4/1)241214/00086

13-3-2019

Pest categorisation of Phymatotrichopsis omnivora

Pest categorisation of Phymatotrichopsis omnivora

Published on: Tue, 12 Mar 2019 The Panel on Plant Health performed a pest categorisation of Phymatotrichopsis omnivora, the causal agent of Phymatotrichum root rot of more than 2,000 dicotyledonous plant species, for the EU. The pest is listed as Trechispora brinkmannii in Annex IAI of Directive 2000/29/EC. P. omnivora is a well‐defined fungal species and reliable methods exist for its detection and identification. It is present in south‐western USA, northern Mexico, Libya and Venezuela. The pest is not...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Pest survey card on Popillia japonica

Pest survey card on Popillia japonica

Published on: Wed, 06 Mar 2019 This pest survey card was prepared in the context of the mandate on plant pest surveillance (EFSA‐Q‐2017‐00831), upon request by the European Commission. The purpose of this document is to assist the Member States in planning annual survey activities of quarantine organisms using a statistically sound and risk‐based pest survey approach, in line with the current international standards. The data requirements for such activity include the pest distribution, its host range, ...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Published on: Tue, 05 Mar 2019 Following a request from European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Robenz® 66G (robenidine hydrochloride (HCl)) when used as a feed additive for chickens for fattening and turkeys for fattening. The coccidiostat Robenz®66G is considered safe for chickens for fattening at the highest proposed level of 36 mg robenidine HCl/kg complete feed with a ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Safety and efficacy of Beltherm MP/ML (endo-1,4-betaxylanase) as a feed additive for piglets, pigs for fattening and other porcine species

Safety and efficacy of Beltherm MP/ML (endo-1,4-betaxylanase) as a feed additive for piglets, pigs for fattening and other porcine species

Published on: Mon, 04 Mar 2019 Beltherm MP/ML contains endo-1,4-beta-xylanase and it is to be used as a zootechnical additive for weaned piglets, pigs for fattening and minor porcine species for fattening. The safety and efficacy of the additive when used for poultry species have been evaluated previously by the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel). In that assessment, the safety for the consumers, environment and the users was assessed. The applicant has ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Safety and efficacy of Beltherm MP/ML (endo‐1,4‐beta‐xylanase) as a feed additive for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding, turkeys for breeding purposes and minor poultry species

Safety and efficacy of Beltherm MP/ML (endo‐1,4‐beta‐xylanase) as a feed additive for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding, turkeys for breeding purposes and minor poultry species

Published on: Fri, 01 Mar 2019 Beltherm MP/ML contains endo‐1,4‐beta‐xylanase and is intended to be used as a zootechnical additive for poultry species. The safety and efficacy of the additive have been evaluated by the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) in 2017. In that assessment, the additive and the production strain, a genetically modified strain of Bacillus subtilis, were characterised in full. No viable cells of the production strain were detecte...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Safety and efficacy of Calsporin® (Bacillus subtilis DSM 15544) for all poultry species

Safety and efficacy of Calsporin® (Bacillus subtilis DSM 15544) for all poultry species

Published on: Fri, 01 Mar 2019 The additive Calsporin® is a preparation of viable spores of Bacillus subtilis DSM 15544, at a minimum declared concentration of 1 × 1010 colony forming units (CFU)/g additive. The additive is authorised as a zootechnical additive (functional group: gut flora stabiliser) for use in chickens for fattening, weaned piglets, chickens reared for laying, turkeys, minor avian species and other ornamental and game birds, laying hens and ornamental fish, dogs, in sows and in suckli...

Europe - EFSA - European Food Safety Authority EFSA Journal

26-2-2019

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Published on: Mon, 25 Feb 2019 Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the product TYFER™ (ferric tyrosine chelate) as zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breeding. The additive is safe for chickens for fattening at the maximum expected level of 200 mg TYFER™/kg complete feed; this conclusion can be extended to chickens reared for laying/breedin...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Published on: Mon, 14 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of B‐Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for fattening or raised for laying. B‐Act® is a preparation containing viable spores of a Bacillus licheniformis strain. This species is considered by EFSA to be suitable for the qua...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Voluntary Recall Notice of El Guapo Chile Habanero and Chile Pasilla-Ancho Pouches Due to Unlabeled Peanut Allergen

Voluntary Recall Notice of El Guapo Chile Habanero and Chile Pasilla-Ancho Pouches Due to Unlabeled Peanut Allergen

Mojave Foods Corporation is initiating a voluntary recall of El Guapo Chile Habanero and Chile Pasilla-Ancho pouches due to an unlabeled peanut allergen.

FDA - U.S. Food and Drug Administration

18-12-2018

Apo-Prednisone 5 mg Tablet (2018-12-18)

Apo-Prednisone 5 mg Tablet (2018-12-18)

Health Canada

11-12-2018

International Lubricants, Inc. recalls Kool-It Evaporator & Heater Foam Cleaner

International Lubricants, Inc. recalls Kool-It Evaporator & Heater Foam Cleaner

The recalled product does not have proper consumer chemical hazard labelling as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act.

Health Canada

27-11-2018

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx 2 Objective 1: Compendium of Representative Processing Techniques investigated in regulatory studies for pesticides

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx 2 Objective 1: Compendium of Representative Processing Techniques investigated in regulatory studies for pesticides

Published on: Mon, 26 Nov 2018 EFSA is conducting pan‐European dietary exposure and risk assessments related to actual levels of pesticide residues in food commodities. These assessments use the pesticide occurrence data generated under the official monitoring programs of Member States, the consumption data from EFSA's comprehensive food consumption database and pesticide‐specific information such as processing factors. Currently no harmonised list of processing factors is available within Europe and wo...

Europe - EFSA - European Food Safety Authority Publications

13-11-2018

Setting of import tolerances for teflubenzuron in grapefruits, mandarins and broccoli

Setting of import tolerances for teflubenzuron in grapefruits, mandarins and broccoli

Published on: Mon, 12 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF Agro BV submitted a request to the competent national authority in the United Kingdom to set import tolerances for the active substance teflubenzuron in grapefruits and mandarins imported from Brazil and for broccoli imported from Paraguay. The data submitted were found to be sufficient to derive maximum residue level (MRL) proposals for grapefruits and broccoli. The MRL derived ...

Europe - EFSA - European Food Safety Authority Publications

10-11-2018

Pest categorisation of Popillia japonica

Pest categorisation of Popillia japonica

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Popillia japonica(Coleoptera: Scarabaeidae) for the EU. P. japonica is a distinguishable species listed in Annex IAII of Council Directive 2000/29/EC. It is native to Japan but established in the USA in the early 20th century. It spreads from New Jersey to most US states east of the Mississippi, some to the west and north into Canada. P. japonica feeds on over 700 plant species. Adults attack folia...

Europe - EFSA - European Food Safety Authority Publications

7-8-2018

Voluntary Recall Notice of El Guapo Jamaica Hibiscus Flower Pouches Due to Unlabeled Peanut Allergen

Voluntary Recall Notice of El Guapo Jamaica Hibiscus Flower Pouches Due to Unlabeled Peanut Allergen

Mojave Foods Corporation is initiating a voluntary recall of four sizes of El Guapo Jamaica Hibiscus Flower packages in flexible packaging due to an unlabeled peanut allergen

FDA - U.S. Food and Drug Administration

9-6-2018

Caito Foods, LLC Voluntarily Recalls Fresh Cut Melon Products Because of Possible Health Risk

Caito Foods, LLC Voluntarily Recalls Fresh Cut Melon Products Because of Possible Health Risk

Caito Foods is voluntarily recalling fresh cut watermelon, honeydew melon, cantaloupe and fresh-cut mixed fruit containing one of these melons, produced at the Caito Foods facility in Indianapolis, because these products have the potential to be contaminated with Salmonella.

FDA - U.S. Food and Drug Administration

3-1-2012

Danish Pharmacovigilance Update, 15 December 2011

Danish Pharmacovigilance Update, 15 December 2011

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.

Danish Medicines Agency

1-12-2011

Danish Pharmacovigilance Update, 17 November 2011

Danish Pharmacovigilance Update, 17 November 2011

In this issue of Danish Pharmacovigilance Update, you can read about domperidone (Motilium® etc.) and potential risk of cardiac disorders, about the European Medicines Agency's recommendation on a lower dose of the antidepressant citalopram as well as about more interesting aspects of pharmacovigilance.

Danish Medicines Agency

7-10-2011

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelat...

Danish Medicines Agency

18-12-2018

APO-Valsartan (valsartan) tablets

APO-Valsartan (valsartan) tablets

Recall - potential contamination

Therapeutic Goods Administration - Australia